Log In
Print
BCIQ
Print
Print this Print this
 

PathFinder TG molecular diagnostic assay for pancreatic cancer

  Manage Alerts
Collapse Summary General Information
Company PDI Inc.
DescriptionAssay that uses loss of heterozygosity (LOH) markers, oncogene mutations and DNA content abnormalities to stratify patients according to their risk of progression to cancer
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose risk of pancreatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$32.0M

$24.5M

$9.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today